Research priorities in hypertrophic cardiomyopathy: report of a Working Group of the National Heart, Lung, and Blood Institute

…, ME Anderson, R Boineau, BJ Byrne, TP Cappola… - Circulation, 2010 - Am Heart Assoc
Cappola … Dr Cappola has received other research support from Abbott Diagnostics. Dr
M. Maron serves as a consultant/advisory board member for PGX Health and Genzyme. …

Patient characteristics associated with telemedicine access for primary and specialty ambulatory care during the COVID-19 pandemic

…, Y Gitelman, DM Kolansky, TP Cappola… - JAMA network …, 2020 - jamanetwork.com
Importance The coronavirus disease 2019 (COVID-19) pandemic has required a shift in
health care delivery platforms, necessitating a new reliance on telemedicine. Objective To …

Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms

…, RW Harrison, MW Skaf, GO Rosas, TP Cappola… - Nature, 2002 - nature.com
Subcellular localization of nitric oxide (NO) synthases with effector molecules is an important
regulatory mechanism for NO signalling 1 . In the heart, NO inhibits L-type Ca 2+ channels …

Multi-ethnic genome-wide association study for atrial fibrillation

…, JA Brody, H Calkins, A Campbell, TP Cappola… - Nature …, 2018 - nature.com
Atrial fibrillation (AF) affects more than 33 million individuals worldwide 1 and has a complex
heritability 2 . We conducted the largest meta-analysis of genome-wide association studies (…

Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy

TP Cappola, DA Kass, GS Nelson, RD Berger… - Circulation, 2001 - Am Heart Assoc
Background Dilated cardiomyopathy is characterized by an imbalance between left ventricular
performance and myocardial energy consumption. Experimental models suggest that …

Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial

…, KJ Anstrom, MR Shah, E Braunwald, TP Cappola… - Jama, 2016 - jamanetwork.com
… Author Contributions: Drs Margulies and Cappola had full access to all of the data in the study
… Dr Cappola reported receiving personal fees from Novartis and Teva Pharmaceuticals. No …

[HTML][HTML] Gene-expression profiling for rejection surveillance after cardiac transplantation

…, RC Starling, MC Deng, TP Cappola… - … England Journal of …, 2010 - Mass Medical Soc
Background Endomyocardial biopsy is the standard method of monitoring for rejection in
recipients of a cardiac transplant. However, this procedure is uncomfortable, and there are risks …

High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure

…, LR Goldberg, M Jessup, TP Cappola - Circulation: heart …, 2011 - Am Heart Assoc
Background— Soluble ST2 reflects activity of an interleukin-33–dependent cardioprotective
signaling axis and is a diagnostic and prognostic marker in acute heart failure. The use of …

Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial

…, CM O'Connor, RE Bonita, KB Margulies, TP Cappola… - Jama, 2013 - jamanetwork.com
… Dr Cappola reports consulting for TEVA Pharmaceuticals and being a coinventor on pending
patents for neuregulin and sFlt-1 as heart failure biomarkers and inventor on a patent for …

Transcriptomic biomarkers of cardiovascular disease

DM Pedrotty, MP Morley, TP Cappola - Progress in cardiovascular …, 2012 - Elsevier
Transcriptomics is the study of how our genes are regulated and expressed in different
biological settings. Technical advances now enable quantitative assessment of all expressed …